Vida Ventures (Vida), a next-generation life sciences venture firm, has closed Vida Ventures III (Vida III) on USD825 million. Vida, founded in 2017, now has over USD1.7 billion of assets under management.
Vida III will build upon the success of Vida’s first two funds and continue its investment approach of identifying and investing in transformative biomedical innovations with the potential to meaningfully impact patients. The capital was raised globally from existing and new blue-chip institutional investors, including top-tier endowments and foundations, sovereign wealth funds, pensions, financial institutions, family offices, fund-of-funds and notable individuals.
Vida has assembled an industry-leading team, including world-class scientific and strategic advisors, who have developed over 25 separate, novel drugs approved by the US Food and Drug Administration. Vida represents depth and breadth of experience in biotechnology, pharmaceuticals, academia, entrepreneurship and investing.
Since inception, Vida has made 30 investments in companies developing transformative therapies for difficult-to-treat indications across oncology, neurology, autoimmunity, rare genetic diseases and beyond. With experience building and scaling companies from concept to commercialisation, Vida takes a hands-on approach and is deeply involved with its portfolio companies across the full life cycle of value creation.
“As investors, company builders and life science supporters, each one of us at Vida is driven by the opportunity to unlock the power of science. From our formation to today with the close of Vida III, the goal is to do our part in converting dreams into groundbreaking therapies for patients. We are grateful to our existing investors who have continued to support us and to those new investors who are partnering with us on the next phase of our journey,” says Dr vArie Belldegrun, MD, FACS, Co-Founder and Senior Managing Director. “Over the last three years, our proven approach to life sciences investing brings together a network of industry experts alongside a powerful investor base undaunted by inherent challenges in drug development, to fundamentally change the course of human disease.”
The success of Vida’s portfolio approach is evidenced by its standout investments that exemplify Vida’s key pillars of strength: connection and access on the ground floor, flexibility to quickly capitalize on opportunistic investments based on broad in-house expertise, and the ability to create the cutting edge by providing hands-on support for young companies on the verge of great breakthroughs.
The Private Funds Group of Jefferies LLC served as exclusive global placement agent for this fundraise. Gunderson Dettmer served as legal adviser.
